WHAT YOU NEED TO KNOW: Recent Study Points to Need for Patent Reform to Balance Competition with Innovation Recently, a new study by Nature Biotechnology revealed many pharmaceutical companies engage in patent thicketing to limit competition from lower-cost alternatives in the marketplace.  Out of the 21 patent lawsuits examined, only 6 percent of patents covered active […]

Continue Reading

Study Finds Pharmaceutical Companies Largely Rely on Low-Quality Patents to Shield Brand-Name Drugs From Biosimilar Competition WASHINGTON, D.C. – This week, Nature Biotechnology released a new study titled, “The Characteristics of Patents Impacting Availability of Biosimilars,” that revealed many pharmaceutical companies engage in patent thicketing to limit competition from lower-cost alternatives in the marketplace.  Out of the […]

Continue Reading

IN CASE YOU MISSED IT: Recently, News Medical Life Sciences reported on a new study by the RAND Corporation that found biosimilar competition in the pharmaceutical marketplace could lower drug prices for numerous medications and lead to $38.4 billion in savings from 2021 to 2025. “This report underlines the increased need for biosimilar competition in the U.S. healthcare […]

Continue Reading

WHAT YOU NEED TO KNOW: New Year, New Ways to Strengthen the U.S. Patent System For too long, some of the largest drug manufacturers have utilized low-quality patents to block market entry of affordable generic alternatives in order to extend exclusivity of their brand name drugs. To combat these anticompetitive tactics, reforms such as the America […]

Continue Reading